Finally, analyses of estrogen receptor positive (ER+) and ER- breast cancer patients showed that DMT1 gene expression downregulation correlates with lower survival in ER-, but in ER+ patients lower DMT1 expression correlates with higher survival (Fig. S4B). This evidence concerns the gene ESR1 and breast carcinoma.